a public good project by the
Synthesis
Company
of California

© 2026

John B.A.G. Haanen | doi.page

0 works0 citations0 h-index

John B.A.G. Haanen

Leiden University Medical Center(NL)University Hospital of Lausanne(CH)The Netherlands Cancer Institute(NL)

Publications by Year

Research Areas

Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management

Most-Cited Works

→ Improved Survival with Ipilimumab in Patients with Metastatic Melanoma(2010)15,035 cited
→ Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma(2015)8,054 cited
→ Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation(2011)7,653 cited
→ Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2017)5,337 cited
→ Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
→ Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma(2019)2,502 cited
→

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2017)

2,321 cited

→ Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.(1991)1,945 cited

→ Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma(2014)1,843 cited

→ Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial(2015)1,372 cited